Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients
NAGIOS: RODERIC FUNCIONANDO

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients

Repositori DSpace/Manakin

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients

Mostra el registre complet de l'element

Visualització       (123.1Kb)

Exportar a Refworks
    
Giménez Quiles, Estela Berenice; Solano Vercet, Carlos; Azanza, José Ramón; Amat Martínez, Paula; Navarro Ortega, David
Aquest document és un/a article, creat/da en: 2014
It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8+ T cells) appeared to perform better for this purpose.

    Antimicrobial Agents and Chemotherapy Vol. 58 Issue 9: pp. 5602-5605
distribuït sota llicència Creative Commons de Reconeixement-NoComercial 3.0 No adaptada

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre complet de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques